18F-FDG PET/CT for Staging and Restaging of Breast Cancer
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Many studies have pointed out the role of (18)F-FDG PET/CT (or (18)F-FDG PET) in patients with clinical stage III or II breast cancer. (18)F-FDG PET/CT might advantageously replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis. We discuss the findings, locoregional or distant, that can be expected in different categories of breast cancer and their impact on prognosis and management. We also discuss the role of (18)F-FDG PET/CT in restaging and how (18)F-FDG PET/CT compares with conventional techniques in restaging for patients with suspected disease recurrence. We conclude with some recommendations for clinical practice and future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029 · cited 12×
“AND INFLAMMATORY BREAST CANCER LABC is variably defined but usually refers to clinical N2, N3, or T4 disease and typically includes American Joint Committee on Cancer (AJCC) clinical stage IIIA (excluding T3N1), IIIB, and IIIC breast cancer (Table 1) (6,7).”
BackgroundMethodInfluentialWeichselbaum, R. R., & Hellman, S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.44 · Cited by 945 · cited 1×
“This impact could be even higher with the development of local control strategies for oligometastatic disease, such as surgery or stereotactic radiotherapy (53,54).”
BackgroundSchnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 649 · cited 1×
“Therefore, the use of PET/CT in such patients is unjustified and exposes women to undue costs and additional anxiety and morbidity associated with false-positive diagnoses (39).”
BackgroundKhatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., Hantel, A., Henry, N. L., Muss, H. B., Smith, T. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9859 · Cited by 626 · cited 1×
“With regard to surveillance, American Society of Clinical Oncology and NCCN guidelines recommend only regular history, physical examination, and mammography for breast cancer routine follow-up (7,57).”
BackgroundCardoso, F., Fallowfield, L., Costa, A., Castiglione, M., & Senkus, E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr372 · Cited by 596
Avril, N., Rosé, C. A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., & Schwaiger, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3495 · Cited by 557
Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., & Senkus, E. (2012) · Annals of Oncology · doi:10.1093/annonc/mds232 · Cited by 485
Groheux, D., Giacchetti, S., Moretti, J.-L., Porcher, R., Espié, M., Lehmann-Che, J., de Roquancourt, A., Hamy, A.-S., Cuvier, C., Vercellino, L., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1640-9 · Cited by 394 · cited 3×
“SUVs are higher in tumors that are negative for hormone receptors (41,42).”
BackgroundSelf-citationWahl, R. L., Siegel, B. A., Coleman, R. E., & Gatsonis, C. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.148 · Cited by 345
Fuster, D., Duch, J., Paredes, P., Velasco, M., Muñoz, M., Santamaría, G., Fontanillas, M., & Pons, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1496 · Cited by 280 · cited 2×
“(14) 2008 P Noninflammatory large BC ($3 cm) 60 Breast MRI, chest CT, liver US, BS Sensitivity and specificity to detect LN involvement were 70% and 100%, respectively Histopathologic confirmation or $1 y of follow-up PET/CT accurately detected unsuspected extraaxillary LN involvement and distant metastases”
BackgroundMethodPerformance of FDG PET/CT in the Clinical Management of Breast Cancer
Groheux, D., Espié, M., Giacchetti, S., & Hindié, E. (2013) · Radiology · doi:10.1148/radiol.12110853 · Cited by 271 · cited 1×
“However, although sclerotic metastases have no 18F-FDG uptake, they show osteocondensation on underlying CT images, so that they can be detected by hybrid PET/CT (36).”
BackgroundSelf-citationBasu, S., Chen, W., Tchou, J., Mavi, A., Cermik, T., Czerniecki, B., Schnall, M., & Alavi, A. (2008) · Cancer · doi:10.1002/cncr.23226 · Cited by 248 · cited 1×
“Triple-negative breast cancer (TNBC; negative for estradiol and progesterone receptors and lacking human epidermal growth factor receptor 2 [HER2] overexpression) is usually highly 18F-FDG–avid (42,43).”
BackgroundIsmail, K., Maissi, E., Thomas, S., Chalder, T., Schmidt, U., Bartlett, J., Patel, A., Dickens, C., Creed, F., & Treasure, J. (2010) · Health Technology Assessment · doi:10.3310/hta14220 · Cited by 245
Oshida, M., Uno, K., Suzuki, M., Nagashima, T., Hashimoto, H., Yagata, H., Shishikura, T., Imazeki, K., & Nakajima, N. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2227::aid-cncr18>3.0.co;2-w · Cited by 230
Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer
Gil-Rendo, A., Martínez-Regueira, F., Zornoza, G., García-Velloso, M. J., Beorlegui, C., & Rodriguez-Spiteri, N. (2009) · British Journal of Surgery · doi:10.1002/bjs.6459 · Cited by 173 · cited 3×
“There is also a positive correlation between the tumor proliferation index (Ki-67 expression) and the intensity of 18F-FDG uptake (41).”
BackgroundKoolen, B. B., Peeters, M.-J. T. F. D. V., Aukema, T. S., Vogel, W. V., Oldenburg, H. S. A., van der Hage, J. A., Hoefnagel, C. A., Stokkel, M. P. M., Loo, C. E., Rodenhuis, S., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1767-9 · Cited by 158 · cited 2×
“In total, there is evidence that PET/CT can advantageously replace conventional imaging for examining extraaxillary nodes, chest, abdomen, and bone in a single session (12,17).”
BackgroundGroheux, D., Giacchetti, S., Delord, M., Hindié, E., Vercellino, L., Cuvier, C., Toubert, M., Merlet, P., Hennequin, C., & Espié, M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.106864 · Cited by 155 · cited 3×
“In total, there is evidence that PET/CT can advantageously replace conventional imaging for examining extraaxillary nodes, chest, abdomen, and bone in a single session (12,17).”
BackgroundSelf-citationPennant, M., Takwoingi, Y., Pennant, L., Davenport, C., Fry-Smith, A., Eisinga, A., Andronis, L., Arvanitis, T., Deeks, J., & Hyde, C. (2010) · Health Technology Assessment · doi:10.3310/hta14500 · Cited by 135 · cited 2×
“Uncertainty remains about its utility as a replacement for conventional work-up rather than as an adjunct to conventional imaging (49).”
BackgroundCooper, K. L., Harnan, S., Meng, Y., Ward, S. E., Fitzgerald, P., Papaioannou, D. E., Wyld, L., Ingram, C., Wilkinson, I. D., & Lorenz, E. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.01.003 · Cited by 134
Effect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer
Groheux, D., Moretti, J., Baillet, G. Y., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.056 · Cited by 122
Self-citationFueger, B. J., Weber, W., Quon, A. S. W., Crawford, T. L., Allen-Auerbach, M., Halpern, B. S., Ratib, O. M., Phelps, M. E., & Czernin, J. G. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0013-4 · Cited by 112
Cochet, A., Dygai‐Cochet, I., Riedinger, J., Humbert, O., Berriolo-Riedinger, A., Toubeau, M., Guiu, S., Coutant, C., Coudert, B. P., Fumoleau, P., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2595-4 · Cited by 100
Self-citationGioia, D. D., Stieber, P., Schmidt, G., Nagel, D., Heinemann, V., & Baur‐Melnyk, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.8 · Cited by 98 · cited 3×
“Compared with conventional imaging, PET/CT provides better prognostic stratification by discriminating patients with locoregional recurrence only from those with distant recurrence (30,34,35) and is helpful for downstaging suspected lesions in some situations (34,50).”
BackgroundCetuximab for the first-line treatment of metastatic colorectal cancer
Meads, C., Round, J., Tubeuf, S., Moore, D., Pennant, M., Bayliss, S., & McCabe, C. (2010) · Health Technology Assessment · doi:10.3310/hta14suppl1-01 · Cited by 80
Pan, L., Han, Y., Sun, X., Liu, J., & Gang, H. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0746-6 · Cited by 77 · cited 1×
“Two metaanalyses compared 18F-FDG PET/CT, conventional imaging (ultrasonography, CT, and bone scintigraphy), and MRI for the detection of breast cancer recurrence (48,49).”
BackgroundOncogene Pathway Activation in Mammary Tumors Dictates FDG-PET Uptake
Alvarez, J. V., Belka, G. K., Pan, T.-C., Chen, C., Blankemeyer, E. R., Alavi, A. A., Karp, J. S., & Chodosh, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1235 · Cited by 72 · cited 1×
“Recent animal data showed that the molecular determinants of 18F-FDG uptake in breast cancer are complex and multifactorial (44).”
BackgroundVeit‐Haibach, P., Antoch, G., Beyer, T., Stergar, H., Schleucher, R. D., Hauth, E., & Bockisch, A. (2007) · British Journal of Radiology · doi:10.1259/bjr/17395663 · Cited by 66
Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma
Manohar, K., Mittal, B. R., Senthil, R., Kashyap, R. K., Bhattacharya, A., & Singh, G. (2012) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3283516716 · Cited by 58
Krammer, J., Schnitzer, A., Kaiser, C. G., Buesing, K. A., Sperk, E., Brade, J., Wasgindt, S., Sütterlin, M., Schoenberg, S. O., Sutton, E. J., et al. (2015) · European Radiology · doi:10.1007/s00330-015-3630-6 · Cited by 57
Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer
Evangelista, L., Baretta, Z., Vinante, L., Cervino, A. R., Gregianin, M., Ghiotto, C., Saladini, G., & Sotti, G. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1626-7 · Cited by 56 · cited 2×
“Compared with conventional imaging, PET/CT provides better prognostic stratification by discriminating patients with locoregional recurrence only from those with distant recurrence (30,34,35) and is helpful for downstaging suspected lesions in some situations (34,50).”
BackgroundHaug, A. R., Schmidt, G. P., Klingenstein, A., et al. (2007) · Journal of Computer Assisted Tomography · doi:10.1097/01.rct.0000284394.83696.42 · Cited by 51
Grassetto, G., Fornasiero, A., Otello, D., Bonciarelli, G., Rossi, E. G., Nashimben, O., Minicozzi, A. M., Crepaldi, G., Pasini, F., Facci, E., et al. (2010) · European Journal of Radiology · doi:10.1016/j.ejrad.2010.04.029 · Cited by 51
Cochet, A., David, S., Moodie, K., Drummond, E. G. P., Dutu, G., MacManus, M. P., Chua, B. H., & Hicks, R. J. (2014) · Cancer Imaging · doi:10.1186/1470-7330-14-13 · Cited by 50 · cited 2×
“Compared with conventional imaging, PET/CT provides better prognostic stratification by discriminating patients with locoregional recurrence only from those with distant recurrence (30,34,35) and is helpful for downstaging suspected lesions in some situations (34,50).”
BackgroundSelf-citationThe Role of Surgery and Ablative Radiotherapy in Oligometastatic Breast Cancer
Salama, J. K., & Chmura, S. J. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.016 · Cited by 33 · cited 1×
“This impact could be even higher with the development of local control strategies for oligometastatic disease, such as surgery or stereotactic radiotherapy (53,54).”
BackgroundChang, H.-T., Hu, C., Chiu, Y., Peng, N., & Liu, R.-S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115127 · Cited by 30 · cited 2×
“described a change in planned management in 10% of patients receiving PET/CT for routine follow-up without suspected relapse before imaging (33).”
Background
Cited by
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Metadata
- Authors
- Groheux, D., Cochet, A., Humbert, O., Alberini, J.-L., Hindié, E., & Mankoff, D.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-02
- Volume
- 57
- Issue
- Supplement 1
- Pages
- 17S-26S
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2256628135
- Cited by
- 201
- References
- 35
- FWCI
- 9.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.